This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2005 by Association Européenne de Recherche en Oncologie.
Recruitment status was:  Recruiting
Roche Pharma AG
Information provided by:
Association Européenne de Recherche en Oncologie Identifier:
First received: September 12, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
To compare maintenance chemotherapy with Xeloda to control after best response with first line chemotherapy in advanced colorectal cancer. Main endpoint is progression free survival. A total of 300 patients will be included.

Condition Intervention Phase
Colorectal Cancer Procedure: Monitoring Procedure: Xeloda Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Association Européenne de Recherche en Oncologie:


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with metastatic colorectal cancer (confirmed histologically) with objective response or stabilization after at least 6 cycles of first line chemotherapy (treatment of choice is selected freely by the investigator according to the recommendations and consensus in force),
  • The interval between completion of first line chemotherapy and randomization should not exceed 4 weeks
  • Age>18 years
  • ECOG status 0 to 2
  • Biological criteria prior to any chemotherapy:

Neutrophils>1.5 109 g/l, platelets>100 109/l, haemoglobin>10 g/dl, Creatininaemia<150 mol/l, bilirubinaemia<2x normal level

  • Signed informed consent
  • Life expectancy > 3 months

Exclusion Criteria:

  • Metastatic colorectal cancer treated with more than one modality of first line chemotherapy (including oral fluoropyrimidines)
  • Tumour progression after first line chemotherapy or before randomization
  • Other tumour pathology
  • Symptomatic cerebral metastases
  • Any severe uncontrolled disease in addition to colorectal cancer (in particular decompensated cardiac failure (LVEF<50%) or coronary insufficiency)
  • Lack of integrity of the upper GI tract: malabsorption syndrome or major surgery of the stomach or the small intestine
  • Severe renal impairment (creatinine clearance < 30 ml/min)
  • Severe psychiatric disorder (other than controlled depressive syndrome)
  • Patient participating in another experiment
  • Pregnant women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00189683

Contact: Annie Jouhaud + 33 1 43 77 72 10

AERO Recruiting
Creteil, France, 94000
Contact: Elizabeth Fabre-Guillevin, MD    + 33 1 43 77 72 10   
Sponsors and Collaborators
Association Européenne de Recherche en Oncologie
Roche Pharma AG
Principal Investigator: Elizabeth Fabre-Guillevin, MD AERO
Principal Investigator: Eric Van Cutsem, MD BGDO
Principal Investigator: Marc Polus, MD BGDO
  More Information Identifier: NCT00189683     History of Changes
Other Study ID Numbers: AERO-MC04
Study First Received: September 12, 2005
Last Updated: September 12, 2005

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on September 20, 2017